ヌベクティス・ファーマ
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.26 | $0 | -$7M |
| 2025 Q4 | -0.31 | $0 | -$4M |
| 2025 Q3 | -0.44 | $0 | -$4M |
| 2025 Q2 | -0.30 | $0 | -$3M |
| 2025 Q1 | -0.27 | $0 | -$4M |
| 2024 Q4 | -0.34 | $0 | -$2M |
| 2024 Q3 |
| -0.24 |
| $0 |
| -$2M |
| 2024 Q2 | -0.26 | $0 | -$3M |